Logo

Products & Services: Mar 26, 2009

Mar 26, 2009
Premium

Pharma IQ will hold a conference next month on the use of oligonucleotides in drug development.

The event will include, among others, sessions on vector-derived RNAi as tools and therapeutics; gene silencing by the gymnotic delivery of oligos; microRNA silencing; and use of miRNAs as biomarkers.

Details about the conference can be found here.

Filed under

Gene Silencing/Gene Editing
RNAi
Breaking News
The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.